Trial Profile
An Open-label Single-dose Pharmacokinetic Study of an Oral Formulation in Tablets Containing Eltrombopag 50 mg (Revolade, Glaxosmithkline Mexico, S.A. De C.V.) in Healthy Volunteers Under Fasting Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Liver cirrhosis
- Focus Pharmacokinetics
- Sponsors GSK
- 07 Oct 2014 New trial record